stockrowNeoGenomics, Inc.
NEO Healthcare Diagnostics & Research
NeoGenomics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $727.3 million, up 10.1% from fiscal 2024.
- Revenue
- +11.4%
- EPS
- +72.1%
- Free cash flow
- −3,724.2%
- Total debt
- +10.9%
Quarter to September 2026, against a year earlier
Follow NEO
Alert me
NeoGenomics, Inc. (NEO) Debt to equity
NeoGenomics, Inc.'s debt to equity at the end of the quarter to 30 September 2026 was 0.5×, up 0.1× from fiscal 2025 (0.4×). Over the past ten years it has ranged from 0.2× (fiscal 2019) to 0.6× (fiscal 2016); the current reading is higher than 45% of that period. That is above the Diagnostics & Research industry median of 0.0× and above the Healthcare sector median of 0.0×.
Debt to equity, annual
Embed this chart
Annual newest first
| Period | Debt to equity | Change |
|---|---|---|
| FY2025 | 0.4× | (31.87%) |
| FY2024 | 0.6× | 4.92% |
| FY2023 | 0.6× | 5.19% |
| FY2022 | 0.5× | 11.42% |
| FY2021 | 0.5× | 91.18% |
| FY2020 | 0.3× | 29.43% |
| FY2019 | 0.2× | (40.42%) |
| FY2018 | 0.3× | (43.25%) |
| FY2017 | 0.6× | (5.77%) |
| FY2016 | 0.6× | 93.86% |
Quarterly newest first
| Period | Debt to equity | Change |
|---|---|---|
| Sep 2026 | 0.5× | (1.70%) |
| Jun 2026 | 0.5× | 16.56% |
| Mar 2026 | 0.4× | 1.05% |
| Dec 2025 | 0.4× | 0.34% |
| 43 more quarters | Free account |
Against its own ten years
Debt to equity against peers
| Company | Debt to equity |
|---|---|
| VCYT Veracyte, Inc. compare | 0.0× |
| CDNA CareDx, Inc. compare | 0.0× |
| FRNM Freenome, Inc compare | 0.0× |
| PSNL Personalis, Inc. compare | 0.0× |
| ADPT Adaptive Biotechnologies Corporation compare | 0.0× |
| CSTL Castle Biosciences, Inc. compare | 0.0× |
| WGS GeneDx Holdings Corp. compare | 0.4× |
| OPK OPKO Health, Inc. compare | 0.4× |
| NEO NeoGenomics, Inc. | 0.5× |
| Diagnostics & Research industry median | 0.0× |
| Healthcare sector median | 0.0× |
| Market median | 0.1× |
What Debt to equity is
Debt to Equity Ratio shows how much a company relies on borrowed money compared with the money its shareholders have in the business.
(Long Term Debt (Total) + Current Part of Debt) ÷ Shareholders Equity (Total)
More on NEO
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement